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1. Introduction 
There is a great body of evidence that a basic 
amino-terminal is essential for the opioid activity of 
enkephalins, Tyr-Gly-Gly-Phe-Met and -Leu [ 1 I, 
and their analogs. Removal of the amino-group of 
Tyr results in a practically inactive peptide [2], as 
does its acetylation [3]. Introduction of two methyl- 
groups into the terminal amino-moiety brings about a 
substantial loss in the biological activity [4], while 
mono-methylation decreases the potency in the mouse 
vas deferens preparation but enhances activity in the 
guinea-pig ileum [S]. It was tempting to speculate 
that interaction between the peptide N-terminus and 
its counterpart on the receptor (presumably a car- 
boxyl-group) might be favourably influenced by 
replacing the terminal amino-group with a guanidino 
function. The resonance stabilized guanidinium 
cation has the capacity to interact.with some bidentate 
structure in the receptor site establishing hydrogen 
bridges in addition to the electrostatic interaction. 
One could anticipate that the improved binding prop- 
erties of the peptide N-terminus would result in 
enhanced biological activity. It has also to be taken 
into account, however, that this replacement leads to 
a distal shift of the positive charge (~1.2 A). Such 
modification at the e-amino group of the lysine side 
chain in certain peptides, i.e., conversion of lysine 
into homoarginine residue, makes the lysine bond 
resistant to trypsin [6]. Thus trypsin seems to be 
unable to combine simultaneously with both the 
carbonyl-group and the positive charge of the basic 
residue when the distance between these is greater 
than occurs in a lysine or arginine residue. In this 
context one may recall that papain, which is less 
specific than trypsin, can hydrolyse homoarginine 
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bonds, though at a lower rate than, for instance, 
arginine bonds [7]. Thus the guanidino-group intro- 
duced into the N-terminus of an enkephalin analog 
may have dual influence on the peptide. For studying 
this problem two tetrapeptideamides and two penta- 
peptideamides related to [D-Met’, Pro’l-enkephalin- 
amide [8] have been synthesized. 
2. Materials and methods 
[D-Met’, Pro’]-Enkephalinamide (Ia) was pre- 
pared by the stepwise synthesis in solution as in [8]. 
A similar procedure was used for the synthesis of des- 
Met5-[D-Met2]enkephalinamide (Ha), des-Met’- 
[D-Nle’] enkephalinamide (IIIa) and [D-Nle’, Pro’] - 
enkephalinamide (IVa). To obtain the corresponding 
guanidino-derivatives I-IV, peptideamide acetates 
Ia-IVa were reacted with I-amidino3, S-dimethyl- 
pyrazole acetate in the presence of triethylamine in 
ethanol at 60-8O’C for 3-4 h. I-IV were purified 
by precipitation from ethanol/ethyl acetate mixture 
or by column chromatography on silica gel using a 
chloroform-25% ammonia-methanol (12:3:8) 
system for elution. RF values found in thin-layer 
chromatography on Kieselgel G in the latter system 
were 0.92-0.97 for compounds Ia-IVa and 0.65- 
0.70 for I-IV. Amino acid analysis after acidic and 
alkaline hydrolyses showed the expected composition. 
Details of the synthesis were described in [9]. The 
agonist activities of the compounds were determined 
in electrically stimulated mouse vas deferens [lO,l l] 
and guinea-pig ileum preparations using both the 
‘single dose’ [12] and ‘multiple dose’ [13] methods 
in the latter system. Antinociceptive properties were 
assessed by the tail-flick test [14] as in [15]. 
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3. Results and discussion 
The structure of the newly synthesized compounds 
and that of [D-Met2, Pro’]-enkephalinamide [8] can 
be described by the general formula X-Tyr-Y-Gly- 
Phe-Q, wherein Q represents the L-prolineamide 
moiety or an amino group, Y stands for D-Met or 
D-Nle and X for hydrogen or an amidino-group. Thus 
the N-terminal residue of the guanidino-terminated 
and the regular amino-terminated peptides can be 
abbreviated as H2N-C (NH)-Tyr and H-Tyr, 
respectively. The opiate activities of the peptides 
assessed in two in vitro assays and in an in vivo test 
for analgesia are summarized in table 1. Regarding the 
agonist activities in vitro it is apparent that guani- 
dination improved the biological potencies of penta- 
peptides as well as the tetrapeptides. The higher 
potencies were obtained in the guinea-pig ileum prep- 
aration. Assessment of IDso values by the ‘single 
dose’ and ‘multiple dose’ methods gave different 
results. The highest deviation (and the highest 
values for agonist activity) was obtained for the 
guanidino derivative of [D-Met’, Pros]-enkephalin- 
amide. These results may raise the intriguing question 
[ 121 whether or not the guanidino-terminated pep- 
tides are of mixed, agonist-antagonist character. It 
also appears that D-Met*-containing peptides possess 
somewhat higher activity than the D-Nle’ analogs 
in vitro. 
However, with respect to analgesic activity, the 
influence of guanidination markedly differs from that 
found in the in vitro assay systems. A guanidino- 
terminal seems to be advantageous only in the tetra- 
peptides. Given intracerebroventricularly (i.c.v.) the 
guanidino derivative of des-Mets-[D-Met2]-enke- 
phalinamide (II) was the most active compound 
showing nearly 20 times higher potency than the 
amino terminated analog, Ha, and 200~times higher 
potency than morphine. When the peptides were 
applied intravenously (i.v.) the guanidino derivative 
of des-Met’-[D-~e2]~nkephalinamide (III) proved 
to be the most potent analgesic, being -2-times more 
Table 1 
Opiate activities of Metenkephalin and its analogs relative to normorphinea (= I, in vitro) and morphineb (= 1, in viva) on a 
molar basis 
Number 
Oi 
compound 
P e p t i d e 
x-Tyr-Y--Sly-Phe----Q 
GPI= GPId ,wae TFRf TFR9 
Ia H o-Met Pro-NH2 7.9 7.9 7.9 64.6 4.2 
I H2N-C/NH/+-MetBro-NH2 823.0 173.0 25.0 10.5 0.65 
IIa H-D-Me t-H2 17.0 17.0 4.1 12.1 2.2 
II H2N-C/NH/-D-Me t-HZ 211:o 79.0 2L.O 210.0 4.4 
IIIa -D-Nle_qH 2 21.7 21.7 8.4 16.4 1.2 
III H2N_C/NH/------D- NleMH2 126.0 79.0 18 .O 20.0 7.95 
IVa _-NleBro-NH2 17.7 17.7 11.6 28.8 1.6 
IV H2N-C/NH/N -Nla.ro-NH2 79.0 21.0 17.0 1.1 0.6 
H--Tyr--Gl.y--Gly-Phedier-OH 
I(et-enkephalin 
0.95 0.95 26.1 co.01 CJ 
a ID,, value was 172.8 nM in the guinea-pig ileum 
b ZD,, values in the rat tail-flick test (depending on the season) were 1.82-2.41/gM/kg on (i.v.1 application and 1.15-6.8 nM/ 
animal on i.c.v. administration, respectively [14,151 
c ‘Single dose’ method in the guinea-pig ileum [ 121 
d ‘Multiple dose’ method in the guinea-pig ileum [ 131 
e Mouse vas deferens preparation [ 10,111 where the ZD,, 
f Tail-flick test in the rat after i.c.v. application 
of normo~h~e was as high as 183.0 nM 
g Tail-flick test in the rat after i.v. application 
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active than [D-Met2, Pro’]enkephalinamide (Ia) and presented by this study it can be concluded that the 
-g-times more potent than morphine. In the case of complexity of events in the CNS resulting in analgesia 
pentapeptides (Ia-1, IVa-IV) guanidination resulted cannot be modelled satisfactorily by the in vitro 
in a substantial loss of analgesic activity. methods. 
To interpret the above phenomenon, it is possible 
that the shift of the positive charge at the N-terminus 
of peptides altered the position (or spatial arrange- 
ment) of the fifth residue, i.e., Pro-NH*, to such an 
extent that for analgesia its absence was more favour- 
able than its presence. 
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It may be noticed that the guanidino terminated 
tetrapeptideamide II and [D-Met’, Pro’l-enkephalin- 
amide (Ia) show an analgesic effect in the CFLP 
mouse also after oral administration. Their potency 
ratios in the acetic acid writhing test are as follows: 
8 and 14 for Ia and II, respectively, relative to mor- 
phine (= 100) on a molar basis. In this context 
[D-Met*, Pro’]enkephalinamide (Ia) has been 
reported inactive in the mouse when given orally 
[ 161. Presumably strain differences and diversity of 
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